Start of main content

Andersen advises NIMGenetics in the capital increase operation by Apposite Capital

| News | Corporate Law and M&A

The firm's Corporate team has provided legal assistance to the biotech multinational in the process of increasing the investment, which places Apposite Capital as the majority shareholder

Andersen, from its Corporate and M&A department, has advised NIMGenetics in the capital increase operation carried out by Apposite Capital, a British Private Equity firm, for six million euros, which are added to the investment already made in 2017, becoming the majority shareholder of the company.

NIMGenetics, specialized within the biotechnology sector in the designing and commercialization of generic clinical diagnostic products and services, has allocated part of the investment to strengthen the team with new additions to accelerate growth at international level, as well as to strengthen agreements with companies in the sector.

Jaime Espejo has led the Andersen team in charge of advising and accompanying NIMGenetics throughout the process. Together with him, Silvio Requena and Jorge Flores, also professionals from Andersen's Corporate and M&A area, have participated in the transaction.

See the article in Europa Press

End of main content